DiaMedica Net Income from 2010 to 2024

DMAC Stock  USD 2.45  0.03  1.24%   
DiaMedica Therapeutics' Net Loss is decreasing over the years with slightly volatile fluctuation. Overall, Net Loss is projected to go to about -18.4 M this year. During the period from 2010 to 2024 DiaMedica Therapeutics Net Loss annual values regression line had coefficient of variation of (67.28) and r-squared of  0.61. View All Fundamentals
 
Net Loss  
First Reported
2005-03-31
Previous Quarter
-4.5 M
Current Value
-5.2 M
Quarterly Volatility
1.4 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check DiaMedica Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DiaMedica main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 K, Interest Expense of 426.2 K or Total Revenue of 0.0, as well as many exotic indicators such as Price To Sales Ratio of 49.24, Dividend Yield of 0.0 or PTB Ratio of 1.72. DiaMedica financial statements analysis is a perfect complement when working with DiaMedica Therapeutics Valuation or Volatility modules.
  
This module can also supplement DiaMedica Therapeutics' financial leverage analysis and stock options assessment as well as various DiaMedica Therapeutics Technical models . Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.

Latest DiaMedica Therapeutics' Net Income Growth Pattern

Below is the plot of the Net Income of DiaMedica Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in DiaMedica Therapeutics financial statement analysis. It represents the amount of money remaining after all of DiaMedica Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is DiaMedica Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in DiaMedica Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (19.38 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

DiaMedica Net Income Regression Statistics

Arithmetic Mean(8,746,008)
Coefficient Of Variation(67.28)
Mean Deviation4,910,867
Median(7,410,961)
Standard Deviation5,884,591
Sample Variance34.6T
Range18.7M
R-Value(0.78)
Mean Square Error14.5T
R-Squared0.61
Significance0.0006
Slope(1,029,405)
Total Sum of Squares484.8T

DiaMedica Net Income History

2024-18.4 M
2023-19.4 M
2022-13.7 M
2021-13.6 M
2020-12.3 M
2019-10.6 M
2018-5.7 M

Other Fundumenentals of DiaMedica Therapeutics

DiaMedica Therapeutics Net Income component correlations

About DiaMedica Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include DiaMedica Therapeutics income statement, its balance sheet, and the statement of cash flows. DiaMedica Therapeutics investors use historical funamental indicators, such as DiaMedica Therapeutics's Net Income, to determine how well the company is positioned to perform in the future. Although DiaMedica Therapeutics investors may use each financial statement separately, they are all related. The changes in DiaMedica Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on DiaMedica Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on DiaMedica Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in DiaMedica Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-19.4 M-18.4 M
Net Loss-18 M-17.1 M
Net Loss-12.2 M-11.6 M
Net Loss(0.60)(0.62)
Net Income Per E B T 1.00  1.12 

Pair Trading with DiaMedica Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DiaMedica Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against DiaMedica Stock

  0.72ELYM Eliem TherapeuticsPairCorr
  0.61ACB Aurora Cannabis TrendingPairCorr
  0.57CGC Canopy Growth Corp TrendingPairCorr
  0.45XFOR X4 Pharmaceuticals Earnings Call This WeekPairCorr
The ability to find closely correlated positions to DiaMedica Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DiaMedica Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DiaMedica Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DiaMedica Therapeutics to buy it.
The correlation of DiaMedica Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DiaMedica Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DiaMedica Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DiaMedica Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
Check out the analysis of DiaMedica Therapeutics Correlation against competitors.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for DiaMedica Stock analysis

When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Money Managers
Screen money managers from public funds and ETFs managed around the world
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.60)
Return On Assets
(0.30)
Return On Equity
(0.47)
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.